- Product Details
Keywords
- DOTA
- 60239-18-1
- DOTA
Quick Details
- ProName: 1,4,7,10-Tetraazacyclododecane-1,4,7,1...
- CasNo: 60239-18-1
- Molecular Formula: C16H28N4O8
- Appearance: Colourless crystals
- Application: For Organic Synthesis use
- DeliveryTime: PROMPT
- PackAge: IN 25kg drums
- Port: SHANGHAI
- ProductionCapacity: 10 Metric Ton/Month
- Purity: 99.0%
- Storage: In Room Temperature
- Transportation: As Per MSDS
- LimitNum: 1 Kilogram
- Moisture Content: N/A
- Impurity: N/A
- Transporttation: N/A
Superiority
DOTA Basic information |
Product Name: | DOTA |
Synonyms: | 1,4,7,10-TETRAAZACYCLODODECANE-1,4,7,10-TETRAACETIC ACID;1,4,7,10-TETRAAZACYCLODODECANE-1,4,7,10-TETRAACETIC ACID, FREE ACID;1,4,7,10-TETRAAZACYCLODODECANE-N,N',N'',N'''-TETRAACETIC ACID;DOTA;TETRAAZA-12-CROWN-4-1,4,7,10-TETRAACETIC ACID;NSC 681107;TETRAXETAN;1,4,7,10-Tetraazacyclododecane-N,N',N'',N'''-tetraaceticacid,min.98%DOTA |
CAS: | 60239-18-1 |
MF: | C16H28N4O8 |
MW: | 404.42 |
EINECS: | |
Product Categories: | Azacrown Ethers;Functional Materials;Macrocycles for Host-Guest Chemistry |
Mol File: | 60239-18-1.mol |
Details
DOTA Basic information |
Product Name: | DOTA |
Synonyms: | 1,4,7,10-TETRAAZACYCLODODECANE-1,4,7,10-TETRAACETIC ACID;1,4,7,10-TETRAAZACYCLODODECANE-1,4,7,10-TETRAACETIC ACID, FREE ACID;1,4,7,10-TETRAAZACYCLODODECANE-N,N',N'',N'''-TETRAACETIC ACID;DOTA;TETRAAZA-12-CROWN-4-1,4,7,10-TETRAACETIC ACID;NSC 681107;TETRAXETAN;1,4,7,10-Tetraazacyclododecane-N,N',N'',N'''-tetraaceticacid,min.98%DOTA |
CAS: | 60239-18-1 |
MF: | C16H28N4O8 |
MW: | 404.42 |
EINECS: | |
Product Categories: | Azacrown Ethers;Functional Materials;Macrocycles for Host-Guest Chemistry |
Mol File: | 60239-18-1.mol |
DOTA Chemical Properties |
mp | 267 °C |
density | 1.321 |
Safety Information |
Hazard Codes | Xi |
Risk Statements | 36/37/38 |
Safety Statements | 26-36 |
WGK Germany | 3 |
F | 3-10-34 |
DOTA Usage And Synthesis |
Chemical Properties | Colourless crystals |
Usage | Bifunctional DOTA aconjugates to peptides and has become an established strategy for constructing target-specific metal containing agents including targeted MRI contrast agents and diagnostic and ther apeutic radiopharmaceuticals. |